According to ACADIA Pharmaceuticals's latest financial reports and stock price the company's current price-to-sales ratio (TTM) is 3.45899. At the end of 2023 the company had a P/S ratio of 7.08.
Year | P/S ratio | Change |
---|---|---|
2023 | 7.08 | 41.98% |
2022 | 4.98 | -35.69% |
2021 | 7.75 | -59.72% |
2020 | 19.2 | -1.79% |
2019 | 19.6 | 88.49% |
2018 | 10.4 | -65.29% |
2017 | 29.9 | -85.14% |
2016 | 202 | -99.66% |
2015 | > 1000 | 126.94% |
2014 | > 1000 | 1220.3% |
2013 | > 1000 | 2761.2% |
2012 | 69.5 | 151.89% |
2011 | 27.6 | 2361.7% |
2010 | 1.12 | -85.83% |
2009 | 7.91 | -62.42% |
2008 | 21.0 | -61.22% |
2007 | 54.3 | 67.72% |
2006 | 32.4 | 113.64% |
2005 | 15.1 | -38.86% |
2004 | 24.8 |
Company | P/S ratio | P/S ratio differencediff. | Country |
---|---|---|---|
Johnson & Johnson JNJ | 4.02 | 16.29% | ๐บ๐ธ USA |
Pfizer PFE | 2.73 | -21.08% | ๐บ๐ธ USA |
Eli Lilly LLY | 20.4 | 489.98% | ๐บ๐ธ USA |
Bristol-Myers Squibb BMY | 1.99 | -42.42% | ๐บ๐ธ USA |
Vanda Pharmaceuticals VNDA | 1.51 | -56.24% | ๐บ๐ธ USA |
Adamas Pharmaceuticals
ADMS | N/A | N/A | ๐บ๐ธ USA |